SCHEDULE: Vanguard Group Discloses 8.65% Stake in Protagonist Therapeutics

The Vanguard Group reported an 8.65% beneficial ownership stake in Protagonist Therapeutics Inc. as of December 31, 2025, following an internal realignment.

Summary

• The Vanguard Group holds beneficial ownership of 5,413,690 shares of Protagonist Therapeutics Inc. Common Stock.
• This ownership represents 8.65% of the class of securities.
• The Vanguard Group has shared voting power over 473,004 shares and shared dispositive power over 5,413,690 shares.
• An internal realignment occurred at The Vanguard Group, Inc. on January 12, 2026, where it ceased performing portfolio management services or administering proxy voting.
• Following the realignment, certain subsidiaries or business divisions of Vanguard are anticipated to report beneficial ownership separately (on a disaggregated basis).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive disclosure, primarily due to the significant institutional ownership by The Vanguard Group, which can instill investor confidence. The internal realignment at Vanguard is an operational detail for the fund manager, not directly impacting Protagonist Therapeutics' fundamentals.

Positives

• The presence of a major institutional investor like The Vanguard Group holding an 8.65% stake in Protagonist Therapeutics Inc. indicates significant institutional confidence in the company.

Negatives

• No specific negative information about Protagonist Therapeutics Inc. is contained within this beneficial ownership report.

Risks

• No company-specific risks are detailed in this beneficial ownership report.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Protagonist Therapeutics Inc.'s operational or financial performance.

Industry Context

StockSavvy.ai notes that significant institutional ownership by firms like Vanguard often signals long-term confidence in a company's prospects, particularly in the volatile biotechnology sector where Protagonist Therapeutics operates. This can provide a degree of stability and validation for other investors.

Comparison to Industry Standards

• StockSavvy.ai observes that Vanguard's investment strategy typically involves broad market exposure and passive indexing, meaning their holdings often reflect a company's inclusion in major indices rather than a specific active bet.
• While not a direct comparison to specific biotech projects, Vanguard's presence in Protagonist Therapeutics is consistent with its role as a major institutional investor in the broader market, similar to holdings by BlackRock or State Street in other biotech firms like Amgen or Gilead Sciences.

Stakeholder Impact

• Shareholders benefit from the transparency of institutional ownership and the potential stability it brings, as a large institutional holder like Vanguard can be seen as a vote of confidence.

Next Steps

• The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses The Vanguard Group's significant beneficial ownership in Protagonist Therapeutics Inc. While a large institutional stake can be a positive signal, the filing does not provide sufficient operational or financial data to make a 'buy' or 'sell' recommendation. It merely confirms a substantial existing position, suggesting a 'hold' is appropriate for investors seeking further fundamental analysis.

Keywords

Protagonist Therapeutics, Vanguard Group, SEC filing, 13G, beneficial ownership, institutional investor, common stock, PTGX